@article{e291331f93354fb38244282938a9b31c,
title = "Flare on serial prostate-specific membrane antigen-targeted 18F-DCFPyL PET/CT examinations in castration-resistant prostate cancer: First observations",
abstract = "A 71-year-old man with castration-resistant prostate cancer demonstrated a flare phenomenon on 99mTc-MDP and CT after 10 weeks of enzalutamide. Prostate-specific membrane antigen-targeted 18F-DCFPyL PET/CT demonstrated minimal uptake at sites of baseline bone and lymph node disease with increasing uptake at sites of osseous disease following therapy. Although this is likely related in part to decreased androgen receptor activity and a consequent increase in prostate-specific membrane antigen expression, other mechanisms (neovascularization, cell infiltration from the bone repair process, osteoblastic turnover, or minimal radiotracer impurity) may also be involved in causing the increased 18F-DCFPyL uptake at sites of osseous flare.",
keywords = "F-DCFPyL, PET/CT, PSMA, Prostate cancer",
author = "Zukotynski, {Katherine A.} and John Valliant and Fran{\c c}ois B{\'e}nard and Rowe, {Steven P.} and Kim, {Chun K.} and Pomper, {Martin G.} and Cho, {Steve Y.}",
note = "Funding Information: Conflicts of interest and sources of funding: M.G.P. is a coinventor on a US patent covering 18F-DCFPyL and as such is entitled to a portion of any licensing fees and royalties generated by this technology. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. S.P.R. and M.G.P. receive research support from Progenics Pharmaceuticals, the licensee of 18F-DCFPyL. S.Y.C. is a consultant for Imaging Endpoints LLC. The following grants are acknowledged: EB024495, CA134675, CA184228, CA183031 and the Movember Foundation (GAP2). No other potential conflict of interest relevant to this article was reported. Publisher Copyright: Copyright {\textcopyright} 2018 Wolters Kluwer Health, Inc. All rights reserved.",
year = "2018",
month = mar,
doi = "10.1097/RLU0000000000001966",
language = "English (US)",
volume = "43",
pages = "213--216",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "3",
}